Fundraising Overview - The company raised a total of RMB 1,283,564,291.24 through a non-public offering of 54,900,098 shares, with a net amount of RMB 1,276,238,913.79 after deducting issuance costs of RMB 7,325,377.45, all funds were received by February 14, 2023 [1][2] Fund Utilization - As of June 30, 2025, the company has utilized RMB 1,160,621,541.60 of the raised funds, with RMB 145,366,012.37 used in the current year, all allocated to fundraising projects [2][4] - The remaining balance in the fundraising account is RMB 149,471,571.45, which includes interest income after deducting bank fees and repayments of loans from the subsidiary [2][3] Fund Management - The company has established a dedicated account management system for the raised funds to ensure compliance with regulations and protect investor interests [2][3] - A tripartite supervision agreement was signed with several banks to manage the dedicated accounts for the raised funds [3] Project Financing - The company approved the use of raised funds to provide loans to its subsidiary, Xinhua Surgical Instruments Co., Ltd., for the expansion of high-end precision minimally invasive surgical instruments production, with a loan limit of RMB 208,725,900 [4] - The company has not used idle funds for temporary working capital or invested in financial products [4] Project Adjustments - The company has made adjustments to the timelines for certain fundraising projects due to delays in procurement, acceptance, and delivery, but these changes do not affect the project implementation entities or investment amounts [4][5] - The company has not changed the investment projects or transferred funds to external parties [4][5] Compliance and Disclosure - The company has complied with the relevant regulations regarding the management and use of raised funds, ensuring timely and accurate disclosures [4][5]